GALT
Galectin Therapeutics Inc

10,447
Mkt Cap
$177.32M
Volume
147,639.00
52W High
$7.13
52W Low
$1.12
PE Ratio
-4.65
GALT Fundamentals
Price
$2.75
Prev Close
$2.80
Open
$2.80
50D MA
$3.02
Beta
0.51
Avg. Volume
246,881.72
EPS (Annual)
-$0.7575
P/B
-1.41
Rev/Employee
$0.00
$173.73
Loading...
Loading...
News
all
press releases
Galectin Therapeutics Highlights Belapectin Data in MASH Cirrhosis KOL Event, Eyes Next Steps
Galectin Therapeutics (NASDAQ:GALT) hosted a virtual key opinion leader (KOL) event to discuss belapectin as a potential treatment for patients with metabolic dysfunction-associated steatohepatitis...
MarketBeat·6d ago
News Placeholder
More News
News Placeholder
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galectin Therapeutics Inc. - GALT
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galectin Therapeutics Inc. - GALT INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of...
PR Newswire·2mo ago
News Placeholder
Galectin Therapeutics Inc. (NASDAQ:GALT) Short Interest Update
Galectin Therapeutics Inc. (NASDAQ:GALT - Get Free Report) was the target of a significant drop in short interest during the month of December. As of December 31st, there was short interest totaling...
MarketBeat·2mo ago
News Placeholder
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galectin Therapeutics Inc. - GALT
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galectin Therapeutics Inc. - GALT INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of...
PR Newswire·2mo ago
News Placeholder
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galectin Therapeutics Inc. - GALT
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galectin Therapeutics Inc. - GALT INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of...
PR Newswire·2mo ago
News Placeholder
Galectin Therapeutics (NASDAQ:GALT) CEO Joel Lewis Sells 18,571 Shares
Galectin Therapeutics Inc. (NASDAQ:GALT - Get Free Report) CEO Joel Lewis sold 18,571 shares of the business's stock in a transaction that occurred on Friday, January 2nd. The stock was sold at an...
MarketBeat·2mo ago
News Placeholder
Khurram Jamil Sells 25,499 Shares of Galectin Therapeutics (NASDAQ:GALT) Stock
Galectin Therapeutics Inc. (NASDAQ:GALT - Get Free Report) insider Khurram Jamil sold 25,499 shares of the business's stock in a transaction on Monday, January 5th. The shares were sold at an average...
MarketBeat·3mo ago
News Placeholder
Insider Selling: Galectin Therapeutics (NASDAQ:GALT) CFO Sells 25,732 Shares of Stock
Galectin Therapeutics Inc. (NASDAQ:GALT - Get Free Report) CFO Jack Callicutt sold 25,732 shares of the stock in a transaction dated Monday, January 5th. The stock was sold at an average price of...
MarketBeat·3mo ago
News Placeholder
Joel Lewis Sells 27,731 Shares of Galectin Therapeutics (NASDAQ:GALT) Stock
Galectin Therapeutics Inc. (NASDAQ:GALT - Get Free Report) CEO Joel Lewis sold 27,731 shares of Galectin Therapeutics stock in a transaction dated Monday, January 5th. The shares were sold at an...
MarketBeat·3mo ago
News Placeholder
Galectin Therapeutics (NASDAQ:GALT) CEO Joel Lewis Sells 37,698 Shares
Galectin Therapeutics Inc. (NASDAQ:GALT - Get Free Report) CEO Joel Lewis sold 37,698 shares of Galectin Therapeutics stock in a transaction on Tuesday, January 6th. The stock was sold at an average...
MarketBeat·3mo ago
<
1
2
...
>

Latest GALT News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.